Fox Business’ Lydia Hu reports on the latest news arising from the pharmaceutical industry as the lack of drugs in the United States reaches a new record.
Fayzer announced on Monday that it stops the development of oral pill after one patient Experienced liver issues.
The company said it had stopped the development of Danuglipron, an oral drug that is investigated to manage chronic weight, after discovering that “the participant in one of the studies of improving the dose suffered from a possible drug injury resulting from the drug”, which was dissolved after the patient stopped using the drug.
Of more than 1,400 people took the drug, the number of cases with high liver enzymes was as with other drugs adopted in the same category.
Sima Sistani CEO of Weightwatches in sudden exit, embraced weight loss medications
“While we are disappointed to stop the development of Danuglipron, we are still committed to evaluating promising programs and growth in their efforts in an attempt to bring innovative new drugs to patients,” Chris Bushev, the chief scientific official in research and development in a statement.
The company said that the data from the second clinical development program in Danuglipron will be presented in a scientific forum or is presented for publication in the magazine of its review from the future peers, although it did not specify when.
Fayzer said it had stopped the development of Danogleberone after the discovery that “the participant in one of the studies of improving the dose suffered a potential drug injury.” (Reuters / Carlo Alegre / Reuters)
The company’s decision is a great setback for the giant of the pharmaceuticals, as it competes with its competitors, Eli Lily and Nofu Nordisk, in the profitable weight loss market. Morgan Stanley Research has re -evaluated the global drug market, and is now expected to reach between 105 billion dollars and 144 billion dollars in 2030. This increases from a previous drop of $ 77 billion. In 2023, sales of obesity with brands with $ 6 billion, according to Morgan Stanley Research.
Doctors draw attention to the safety issues related to the high weight loss drugs
Competition in space intensifies, with Novo Nordisk and Elie Lily competing for dominance by reducing their cost Popular weight loss medications For patients who pay money-the effective accession range for those who do not have insurance through their self-payment pharmacy programs.
Pfizer competes with its competitors ELI Lilly and Novo Nordisk in the profitable weight loss market. (Scanpix Denmark / Liselotte Sabroe via Reuters / Reuters photos)
This is not the first relapse of Danogleberone from Phazer. The company has developed it Birth control pills twice a day to lose weight In 2023, after a clinical trial, “high rates” showed the harmful side effects among users.
At that time, the company said, “The most common negative events were moderate and exhausted in nature in line with the mechanism,” but many people suffered from nausea, up to 73 %, vomiting, up to 47 %, and diarrhea, up to 25 %.
| index | protection | last | Changing | % Change |
|---|---|---|---|---|
| PFE | Pfizer Inc. | 21.91 | +0.32 |
+1.48 % |
| To | Eli Lily and Partners. | 732.41 | +11.50 |
+1.60 % |
| Non -governmental organizations | Novo Nordisk A/S. | 64.73 | +3.52 |
+5.75 % |
Get Fox Business on the Go by clicking here
He added: “The high stop rates, which are more than 50 %, were seen in all doses compared to about 40 % with the imaginary medicine.”
Fox Business Greg Norman contributed to this report.
https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2022/08/0/0/c76c6d16-2020-11-09T171237Z_590081288_RC2TZJ95OGP6_RTRMADP_3_HEALTH-CORONAVIRUS-VACCINES-PFIZER.jpg?ve=1&tl=1
Source link